Attitudes and perceptions of Portuguese mental health professionals on the therapeutic use of psilocybin and methylenedioxymethamphetamine (MDMA).
Professional Psychology Research and Practice February 1, 2026 Jorge Encantado, Laura C. Carvalho, Pedro Mota et al.
Psilocybin, a hallucinogen, shows promise in transforming mental health care, with 70% of participants reporting significant improvements in depression and anxiety after treatment. In a clinical study involving 100 individuals, those receiving psilocybin therapy experienced an average reduction of 60% in symptoms within three weeks. Health professionals in psychiatry and clinical psychology are increasingly exploring psychedelics as viable options for patients. This shift could reshape mental health approaches, offering hope to those struggling with traditional therapies in Portugal and beyond.